20:15 , Mar 23, 2018 |  BioCentury  |  Emerging Company Profile

Double threat

Boston Immune Technologies & Therapeutics Inc. is developing potentially first-in-class TNFR2 inhibitors that have the dual effect of killing both tumor cells and immunosuppressive Tregs. President and CEO Russell LaMontagne said tumor necrosis factor receptor...